Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after its Q4 results. The firm expects the benefits from both the Medicare redesign and CKD to materialize in Q3 and be more pronounced in Q4, though it also sees sales in Q1 to be lower than Q4 sales due to healthcare plans and deductibles resetting, the analyst tells investors in a research note. Maxim adds that the management’s various initiatives to accelerate Furoscix sales trajectory are now coming to fruition, also stating that the market opportunity for chronic heart failure and CKD patients remains significant and Furoscix continues to see positive reception and adoption.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH:
- Promising Growth Trajectory and Strategic Expansion Drive Buy Rating for scPharmaceuticals
- Strong Growth Prospects for scPharmaceuticals: Buy Rating Justified by Furoscix Success and Strategic Expansion
- scPharmaceuticals Reports Strong Revenue Growth in 2024
- scPharmaceuticals reports Q 4EPS (35c), consensus (39c)
- Options Volatility and Implied Earnings Moves Today, March 19, 2025
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue